RxDoctor Payments Data

Alok Jain, MD

Psychiatry · Springfield, MONPI 1285630095

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,540 of the $64,137 with a category attached, or 66.3%. 35 manufacturers reported payments, led by AbbVie at 53.7% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,137in general payments, 2019–2025

Across 716 payments — averaging $89.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$34K
  • Supernus Pharmaceuticals, Inc.$13K
  • E.r. Squibb & Sons, L.L.C.$11K
  • Otsuka America Pharmaceutical, Inc.$861
  • Alkermes, Inc.$639
  • Neurocrine Biosciences, Inc.$604
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$8,39513%
  • Speaking & faculty fees$42,54066%
  • Travel & lodging$2,8104%
  • Food & beverage$10,18216%
  • Education$2110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,137 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$38,368
Medicare patients
107
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl37$63,669
CaplytaLumateperone Tosylate15$20,392
TrintellixVortioxetine Hydrobromide14$6,653
Clozapine50$3,125
Ziprasidone Hcl29$2,327
Lurasidone Hcl23$2,023
Trazodone Hcl66$1,132
Oxcarbazepine22$958
Divalproex Sodium ErDivalproex Sodium21$787
Methylphenidate Hcl20$618
Mirtazapine33$615
Aripiprazole15$587
Quetiapine Fumarate18$535
Bupropion XlBupropion Hcl17$331
Atorvastatin Calcium24$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$363$63,66937 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$363$20,39215 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$263$6,65314 claims
Almatica Pharma LLCSertraline Hcl$31$9111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →